Maureen Murphy

Professor and Program leader

The Wistar Institute
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (13)

Year:

2026

Year:

2026

The pathogenesis of many rare tumor types is poorly understood, preventing the design of effective treatments. Solitary fibrous tumors (SFTs) are neoplasms of mesenchymal origin that affect 1/1,000,000 individuals every year and are clinically assimilated to soft tissue sarcomas. SFTs can arise throughout the body and are usually managed surgically. However, 30–40% of SFTs will relapse local-regionally or metastasize. There are no systemic therapies with durable activity for malignant SFTs to date. The molecular hallmark of SFTs is a gene fusion between the NAB2 and STAT6 loci on chromosome 12, resulting in a chimeric protein of poorly characterized function called NAB2-STAT6. We use primary samples and an inducible cell model to discover that NAB2-STAT6 operates as a transcriptional coactivator for a specific set of enhancers and promoters that are normally targeted by the EGR1 transcription factor. In physiological conditions, NAB2 is primarily localized to the cytoplasm and only a small nuclear fraction is available to operate as a co-activator of EGR1 targets. NAB2-STAT6 redirects NAB1, NAB2, and additional EGR1 to the nucleus and bolsters the expression of neuronal EGR1 targets. The STAT6 moiety of the fusion protein is a major driver of its nuclear localization and further contributes to NAB2’s co-activating abilities. In primary tumors, NAB2-STAT6 activates a neuroendocrine gene signature that sets it apart from most sarcomas. These discoveries provide new insight into the pathogenesis of SFTs and reveal new targets with therapeutic potential.

Year:

2025

Supplementary Figure S1. The Y107H variant of p53 is comparable to WT p53 for growth suppression and apoptosis. Supplementary Figure S2. The Y107H variant is impaired for transactivation of a subset of p53 target genes, including PADI4, PLTP, and HHAT. Supplementary Figure S3. The Y107H protein is impaired for binding to p53 response elements. Supplementary Figure S4. Structural analysis of the Y107H variant shows similar structure but decreased thermal stability and increased propensity to misfold into mutant p53 conformation. Supplementary Figure S5. Mice with the Y107H variant have increased cancer risk. Supplementary Figure S6. Colorectal cancer cells harboring hypomorphic variants have increased sensitivity to the glutaminase inhibitor CB-839. Supplementary Figure S7. PADI4 is a p53 target and has tumor suppressive activity. Supplementary Figure S8. PADI4 correlates with increased immune signatures and wild-type p53 in human cancers.

Year:

2025

The pathogenesis of many rare tumor types is poorly understood, preventing the design of effective treatments. Solitary fibrous tumors (SFTs) are neoplasms of mesenchymal origin that affect 1/1,000,000 individuals every year and are clinically assimilated to soft tissue sarcomas. SFTs can arise throughout the body and are usually managed surgically. However, 30–40% of SFTs will relapse local-regionally or metastasize. There are no systemic therapies with durable activity for malignant SFTs to date. The molecular hallmark of SFTs is a gene fusion between the NAB2 and STAT6 loci on chromosome 12, resulting in a chimeric protein of poorly characterized function called NAB2-STAT6. We use primary samples and an inducible cell model to discover that NAB2-STAT6 operates as a transcriptional coactivator for a specific set of enhancers and promoters that are normally targeted by the EGR1 transcription factor. In physiological conditions, NAB2 is primarily localized to the cytoplasm and only a small nuclear fraction is available to operate as a co-activator of EGR1 targets. NAB2-STAT6 redirects NAB1, NAB2, and additional EGR1 to the nucleus and bolsters the expression of neuronal EGR1 targets. The STAT6 moiety of the fusion protein is a major driver of its nuclear localization and further contributes to NAB2’s co-activating abilities. In primary tumors, NAB2-STAT6 activates a neuroendocrine gene signature that sets it apart from most sarcomas. These discoveries provide new insight into the pathogenesis of SFTs and reveal new targets with therapeutic potential.

Year:

2025

TP53 is the most frequently mutated gene in cancer, yet key target genes for p53-mediated tumor suppression remain unidentified. Here, we characterize a rare, African-specific germline variant of TP53 in the DNA-binding domain Tyr107His (Y107H). Nuclear magnetic resonance and crystal structures reveal that Y107H is structurally similar to wild-type p53. Consistent with this, we find that Y107H can suppress tumor colony formation and is impaired for the transactivation of only a small subset of p53 target genes; this includes the epigenetic modifier PADI4 , which deiminates arginine to the nonnatural amino acid citrulline. Surprisingly, we show that Y107H mice develop spontaneous cancers and metastases and that Y107H shows impaired tumor suppression in two other models. We show that PADI4 is itself tumor suppressive and that it requires an intact immune system for tumor suppression. We identify a p53–PADI4 gene signature that is predictive of survival and the efficacy of immune-checkpoint inhibitors. Significance: We analyze the African-centric Y107H hypomorphic variant and show that it confers increased cancer risk; we use Y107H in order to identify PADI4 as a key tumor-suppressive p53 target gene that contributes to an immune modulation signature and that is predictive of cancer survival and the success of immunotherapy. See related commentary by Bhatta and Cooks, p. 1518. This article is highlighted in the In This Issue feature, p. 1501

Year:

2025

Supplementary Figure S1. The Y107H variant of p53 is comparable to WT p53 for growth suppression and apoptosis. Supplementary Figure S2. The Y107H variant is impaired for transactivation of a subset of p53 target genes, including PADI4, PLTP, and HHAT. Supplementary Figure S3. The Y107H protein is impaired for binding to p53 response elements. Supplementary Figure S4. Structural analysis of the Y107H variant shows similar structure but decreased thermal stability and increased propensity to misfold into mutant p53 conformation. Supplementary Figure S5. Mice with the Y107H variant have increased cancer risk. Supplementary Figure S6. Colorectal cancer cells harboring hypomorphic variants have increased sensitivity to the glutaminase inhibitor CB-839. Supplementary Figure S7. PADI4 is a p53 target and has tumor suppressive activity. Supplementary Figure S8. PADI4 correlates with increased immune signatures and wild-type p53 in human cancers.

Year:

2024

Supplementary Figure S1. The Y107H variant of p53 is comparable to WT p53 for growth suppression and apoptosis. Supplementary Figure S2. The Y107H variant is impaired for transactivation of a subset of p53 target genes, including PADI4, PLTP, and HHAT. Supplementary Figure S3. The Y107H protein is impaired for binding to p53 response elements. Supplementary Figure S4. Structural analysis of the Y107H variant shows similar structure but decreased thermal stability and increased propensity to misfold into mutant p53 conformation. Supplementary Figure S5. Mice with the Y107H variant have increased cancer risk. Supplementary Figure S6. Colorectal cancer cells harboring hypomorphic variants have increased sensitivity to the glutaminase inhibitor CB-839. Supplementary Figure S7. PADI4 is a p53 target and has tumor suppressive activity. Supplementary Figure S8. PADI4 correlates with increased immune signatures and wild-type p53 in human cancers.

Year:

2024

Year:

2023

Year:

2022

Year:

2021

Year:

2021

Year:

2020

Collaborators (12)

Yulia Nefedova

The Wistar Institute

UNITED STATES
View details

Sven Miller

Assistant Research Professor

Fox Chase Cancer Center

UNITED STATES
View details

Kara Maxwell

Assistant Professor

University of Pennsylvania

UNITED STATES
View details

Toshitha Kannan

The Wistar Institute

UNITED STATES
View details

Judy Garber

Chief, Division of Cancer Genetics and Prevention

Dana-Farber Cancer Institute

UNITED STATES
View details

James Dougherty

The Wistar Institute

UNITED STATES
View details

Huma Rana

Dana-Farber Cancer Institute

UNITED STATES
View details

Alison Schwartz

Dana-Farber Cancer Institute

UNITED STATES
View details

Robert G. Maki

Professor, Member

-

UNITED STATES
View details

Andrew Kossenkov

Assistant Professor

The Wistar Institute

UNITED STATES
View details

Noam Auslander

Assistant professor

The Wistar Institute

UNITED STATES
View details

Qin Liu

Professor

The Wistar Institute

UNITED STATES
View details